-
The peptide drug market has broad prospects, but it still faces 3 major challenges
Time of Update: 2022-05-02
Compared with small molecules, the development of peptide drugs is more complicated, and the company may not be able to meet the challenges by itself, and it needs to cooperate with other companies at different stages .
At present, domestic companies in the CDMO field of peptide drugs include Ambio Pharmaceuticals, Sino Bio, Nuotai Bio, Asymchem, etc.
-
Phase 3 clinical results of innovative peptide-conjugated drugs for the treatment of multiple myeloma are positive
Time of Update: 2021-06-01
On May 25, 2021, Oncopeptides AB announced that its peptide-conjugated drug Pepaxto (melphalan flufenamide) has achieved positive results in a phase 3 clinical trial for the treatment of relapsed/refractory multiple myeloma (R/R MM).
-
Express | Treatment of multiple myeloma, innovative peptide-conjugated drugs Phase 3 clinical results are positive
Time of Update: 2021-06-01
▎ WuXi AppTec content team editor May 25, 2021, Oncopeptides AB announced that its peptide-conjugated drug Pepaxto (melphalan flufenamide) is in the treatment of relapsed/refractory multiple myeloma (R/R MM) phase 3 clinical trial Positive results were obtained in the experiment.
-
"First-in-class" peptide-conjugated drug obtained accelerated FDA approval; Eli Lilly's innovative diabetes treatment reached phase 3 clinical endpoint
Time of Update: 2021-03-23
"Baricitinib is currently in another phase 3 clinical trial for the treatment of patients with alopecia areata, and the results are expected to be announced in the first half of this year.
-
Zealand Pharma's peptide-based therapy dasiglucagon Phase 3 clinical trial reaches primary and secondary end points of trial
Time of Update: 2020-06-09
today, The http:// of The Peptide-based Therapy developed by The Company has reached the primary end and all critical secondary endpoints in the validation of the Phase 3 Clinical Trial (http://